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A large gap between the number of people with end-stage kidney disease (ESKD) who received 
kidney replacement therapy (KRT) and those who needed it has been recently identified, and it is 
estimated that approximately one half to three quarters of all people with ESKD in the world may 
have died prematurely because they could not receive KRT. This estimate is aligned with a previous 
report that estimated that more than 3 million people in the world died each year because they could 
not access KRT. In this article, we discuss the reasons for the differences in treated and untreated 
ESKD, KRT modalities and outcomes, and present strategies to close the global KRT gap by 
establishing robust health information systems to guide resource allocation to areas of need, inform 
KRT service planning, enable policy development, and monitor KRT health outcomes.  
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Chronic kidney disease (CKD) is associated with increased risks of morbidity, mortality, and excess 
healthcare costs for individuals, families, and countries.1.2 Whereas global rates of death and 
disability-adjusted life years have decreased for most non-communicable diseases over the past two 
decades, corresponding rates for CKD have overall increased.3-5 Indeed, recent data from the Global 
Burden of Disease study have predicted that CKD will be the 5th leading cause of death by the year 
2040.6 
The progression from the early stages of CKD to end-stage kidney disease (ESKD) exerts a 
multiplying effect on morbidity, mortality, and healthcare costs. Life expectancy is drastically 
shortened in these individuals, unless life-saving, costly kidney replacement therapy (KRT; dialysis or 
kidney transplantation) is initiated. A recent systematic review of data from 123 countries 
(representing 93% of the world’s population) estimated that 2.618 million people received KRT 
worldwide in 2010 and that this figure would more than double to 5.439 million people by 2030, with 
most of the growth occurring in low and middle-income countries in Asia and Latin America.7 
More importantly, it was reported that there was a large gap between the number of people with 
ESKD who received KRT and those who needed it, such that between 2.284 and 7.083 million 
people, representing about one half to three quarters of all people with ESKD in the world, may have 
died prematurely because they could not receive KRT.7 This estimate is aligned with a previous 
report8 that estimated that more than 3 million people in the world died each year because they could 
not access KRT. In this article, we discuss the reasons for the differences in treated and untreated 
ESKD, KRT modalities and outcomes, and present strategies to decrease these gaps through the 
improvement of health information systems.  
Global differences in KRT incidence and prevalence 
Available registry data indicate that the prevalence of treated ESKD varies more than 1000-fold 
across the globe from close to zero per million population (pmp) to over 2000 pmp in parts of North 
and East Asia, suggesting the presence of large inequities in global access to KRT.9-12 The majority of 
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all ESKD patients treated with KRT reside in North America, Japan, or Europe,9,13,14 and socio-
economic factors are likely to be a major driver for these differences, since KRT prevalence is highly 
correlated with countries’ wealth and investments in healthcare.7,14,15 Approximately 93% of 
individuals receiving KRT in 2010 resided in high- or upper-middle-income countries (UMIC), such 
that there was a 70-fold greater prevalence of KRT use in these countries compared with their low- 
and lower-middle-income country (LMIC) counterparts.7,16,17 Despite this, the numbers of patients on 
KRT in regions such as Latin America and Asia are quickly increasing, most likely as a consequence 
of economic improvements and public policies that allow increased access and more universal 
coverage to ESKD treatment.7 High-income countries (HIC) that provide KRT typically spend 
approximately 2-3% of their national healthcare budgets on patients with ESKD, despite the fact that 
such patients represent only 0.1%-0.2% of the total population.5,11  
Appreciable between-country variation in KRT use has also been observed according to age 
(particularly older people), sex, race (particularly black and indigenous peoples), and migrant 
populations.9,18 The reasons for these variations remain unclear, but may potentially reflect a number 
of factors including patient-related issues (e.g. age, presence of comorbidities, individual preference, 
distance of residence from a renal unit, educational and socio-economic status, beliefs, health literacy, 
etc.), healthcare system-related factors (e.g. presence of a universal primary care system to manage 
diabetes, hypertension and other risk factors, presence of a CKD care plan, presence of adequately 
trained workforce, broader public coverage of dialysis and transplantation, physician bias and 
experience, renal unit distribution, etc.) and quality of local or national registries. In some LMIC, 
there are emerging programs of government-funded chronic dialysis for ESKD which offer treatment 
to adults but not sufficiently for children.19 
Global differences in KRT modality 
The most common (78%) form of KRT is dialysis, of which 89% is accounted for by hemodialysis 
(HD) and 11% by peritoneal dialysis (PD) globally.7,20 A recent evaluation of the current status of 
global kidney care in 124 countries, comprising 93% of the world’s population, performed by the ISN 
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Global Kidney Health Atlas (GKHA) Project observed that HD was available in all of countries from 
where responses were available, but PD was available in just 80%, and in only 29% of low-income 
countries (LIC).10,11 This observation seems somewhat paradoxical, since PD has a number of features 
that should be attractive to LIC including fewer technical demands, greater feasibility of use in remote 
regions, lesser need for trained staff, and fewer management challenges in the setting of natural 
disasters. PD may also be an attractive modality in many countries in terms of cost, understanding that 
comparative cost of dialysis modality varies depending on the region, and the fact that there is no 
adequately performed cost-effectiveness studies comparing HD vs PD in most regions.21-23 For these 
reasons, countries like Thailand, Hong Kong, New Zealand, Australia, China and USA, have enacted 
public policies that promote and/or provide financial incentives for preferential use of PD.10,24-27 
Nevertheless, the relative use of PD versus HD varies markedly between countries and can be related 
to variability in patient factors (e.g. awareness, comorbidities, visual acuity, dexterity, mobility, 
cognitive ability, family support, financial status), facility factors (e.g. physician bias and experience, 
physician availability, surgeon availability, infrastructure support for urgent-start PD, PD and HD 
training processes, private versus public), healthcare system factors (e.g. public vs. private models, 
financial incentives, clinician and particularly nursing reimbursement, dialysis policy) and industry 
factors (e.g. local fluid manufacture, solution costs).20,28 Other models of care delivery, including 
point of care dialysate production, (i.e. the Affordable Dialysis Project), simple technology 
equipment, semi- or self-care KRT, community-based centers, will need to be considered as potential 
alternatives in specific regions taking into account the local reality. 
The availability of dialysis does not necessarily equate with accessibility, which may be further 
limited within and between countries. In the GKHA survey, the key barriers to providing KRT 
identified by country representatives were geographical (71% - distance from care or prolonged travel 
time), physician-related (65% - availability, access, knowledge, and attitude), patient-related (78% - 
knowledge and attitude) and healthcare system-related (20% - availability, access, capability).10,11 
These barriers were specifically identified in the ISN Collection Survey, which reported that age, co-
morbidities, and availability of a transplant donor were taken into account for the decision of 
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providing access to KRT in several LMIC.29 Nevertheless, the most important barrier to KRT in LIC 
and LMIC is treatment cost; financial factors and out of pocket expenses also play a role in dialysis 
accessibility, since the cost of dialysis for a patient exceeds the average annual individual income in 
most countries30 and one-third of countries exclude dialysis from public funding.10,11 This is an even 
greater issue for people living in LIC where dialysis is excluded from public funding in the majority 
of instances.10,11 
Utilization of kidney transplantation, which accounts for 22% of all KRT,7 is also highly variable 
within and between countries,10,11 even though this KRT modality is associated with superior survival, 
quality of life, and cost-effectiveness.31 According to the GKHA, kidney transplantation was not 
available in 21% of countries surveyed,10,11 including 64% of African countries and 88% of LIC.10,11 
In those countries where it was available, transplant rates varied more than 70-fold from <1 pmp in 
Bangladesh to 71 pmp in the Jalisco state of Mexico.9 Rates of kidney transplantation also vary 
appreciably according to patient characteristics, including age, gender, race, socio-economic status, 
and health insurance status.13,32-35 Access to transplantation is often influenced by the affordability of 
transplant medications, which were reported to be publicly funded by the government and free at the 
point of delivery in less than 30% of all countries surveyed in the GKHA. In 53% of LIC, transplant 
medications were funded through solely private and out of pocket sources.10,11 Cultural background 
about receiving and/or donating organs from brain death donors, such as in Japan, China, and Taiwan, 
may also limit kidney transplantation.30,36 The proportions of living donor kidney transplants 
performed also vary markedly around the world, ranging from 0% in Morocco and Greece through to 
100% in Iceland, Egypt, and Bangladesh.9 The majority of LIC (100%) and LMIC (62%) perform 
solely living donor kidney transplants.  
Although the evidence indicates that the majority of patients with ESKD in the world do not receive 
KRT, it is unclear to what extent in each country this reflects unrecognized ESKD (thereby preventing 
KRT being offered), difficulty accessing KRT due to the various patient and healthcare-related factors 
described previously, or medically informed patient choice to receive comprehensive conservative 
care (also known as non-dialysis supportive care). Whilst comprehensive conservative care has been 
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widely recognized and provided,37-40 the incidence or prevalence of this treatment pathway has been 
poorly studied.41 A survey of comprehensive conservative care practice patterns in relation to older 
(≥75 years old) patients was administered to all 71 adult renal units in the United Kingdom in 2013 
and demonstrated that comprehensive conservative care was practiced in almost all units but varied 
markedly in its scale and approach between centers.42 In a community-based cohort study of over 1.8 
million adults in Alberta, Canada, the incidence of treated and untreated ESKD was 0.18% and 
0.17%, respectively, over a median follow-up period of 4.4 years.43 Compared with young adults, 
rates of untreated ESKD were over 5-fold higher in patients aged ≥85 years.43 Similar findings were 
observed in a population-based study in Australia.44 As dialysis registries are patchy around the world 
and as most dialysis registries do not capture patients who do not access dialysis for whatever reason, 
the precise frequency of occurrence and reasons for ESKD not being treated are unknown, particularly 
in LIC. 
Thus, global access to KRT is both poor and inequitable, and the majority of people with ESKD in the 
world die prematurely because of lack of access to KRT. In the following sections, we discuss the 
importance of, and define potential actions to improve the capturing and monitoring of global 
differences in the incidence and prevalence of ESKD, ESKD care, and modality of ESKD care. 
The importance of health information systems in ESKD care planning and delivery 
It is difficult to manage a problem unless it can be measured. Therefore, a cornerstone of closing the 
global KRT gap is establishing robust health information systems in each country to define CKD and 
ESKD burdens, guide resource allocation to areas of need, identify KRT access blocks, capture costs 
and funding of treatment, inform KRT service planning, enable policy development, and monitor 
KRT health outcomes, particularly following interventions.  
According to the GKHA survey, only 62% of countries could estimate their prevalence of kidney 
disease10,11 through KRT registries. This figure fell to 24% in LIC.10,11 Only 8% of countries had a 
national non-dialysis CKD registry.10,11 With respect to dialysis registries, 64% of countries had a 
national or regional dialysis registry (HIC 89%, UMIC 73%, LMIC 50%, LIC 18%).10,11 African 
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(35%) and South Asian (40%) countries had the lowest frequencies of dialysis registries. Similar 
findings were observed for kidney transplantation, for which only 58% of countries had a national or 
regional registry (HIC 89%, UMIC 67%, LMIC 44%, LIC 0%).10,11 Only 19% of African countries 
had a transplant registry. The Latin American Dialysis and Renal Transplant Registry (LADRTR) 
captures data on KRT (including dialysis and transplantation) combining national registries from 20 
Latin American-affiliated countries since 1991, covering 95% of the population for this region. 
However, the Registry has some limitations as most nations do not have formal registries and in most 
of those that have them, reporting to the existing registry is not mandatory, generating potential 
information gaps.45 Several heavily populated countries, including India, Germany, and a number of 
African countries collectively representing over 20% of the world’s population, do not have any 
CKD, KRT, or acute kidney injury registries (AKI) (Figure 1).46 
The lack of comprehensive health information systems, particularly in LIC, to accurately capture 
CKD/ESKD burden and KRT provision needs to be addressed as a matter of priority, given that KRT 
is associated with substantial health care costs. The current data pertaining to ESKD 
incidence/prevalence and the gap between KRT need and use are based on modeling projections from 
limited regional/national registry data pertaining to dialysis with or without kidney transplantation and 
adjusted for limited variables, such as country income and life expectancy.7 Data collection 
methodologies and analyses also vary considerably between countries. Consequently, the degree and 
reliability of within- and between-country variation in the prevalence of treated ESKD remain 
uncertain. Data pertaining to the number of ESKD patients requiring KRT are even less certain. In the 
study by Liyanage et al,7 low and high estimates were respectively developed from age-specific KRT 
data from 16 HIC with incomplete KRT uptake and 4 HIC (Japan, Singapore, Taiwan, and the USA) 
in which KRT was presumed to be provided to almost all individuals needing it. The uncertainties 
regarding the true incidence and prevalence of treated and untreated ESKD are greatest in LIC and 
LMIC. 
Initiatives to implement KRT registries in LMIC 
 
 11 
Some LMIC across the world have managed to establish dialysis registries. Africa, Chad, Guinea, and 
Niger have recently implemented KRT registries. Indeed, Guinea additionally has non-dialysis CKD 
and AKI registries. The experiences of these countries could be drawn upon to help establish 
registries in other African countries. Other successful African renal registries, such those established 
in Tunisia in 199047 and South Africa,48 demonstrate the powerful potential for registries to highlight 
inequitable KRT access and help inform policy decisions in favor of providing additional resources 
for treating ESKD.47 Similar experiences have been reported following the establishment of renal 
registries in other countries, such as Thailand,49 Malaysia,50 and Latin America.51 
A number of LMIC are in the process of setting up national dialysis registries. The LADRTR was 
created in 1991, and since then, it has published several reports (http://test1.slanh.net/wp-
content/uploads/2018/10/INFORME-2015-2016.pdf). As the registry is not mandatory, it has required 
a sustained effort from the Latin American Nephrology community. Twenty countries participated in 
the surveys (>90% of the region). In principle, a wide variability in kidney disease is observed in the 
region. The mean prevalence of KRT is 776 patients pmp (ranging from 199 in Paraguay to 1881 in 
Puerto Rico), the mean incidence is 162 pmp (23 Paraguay - 420 Mexico) and the mean rate of kidney 
transplantation is 26 pmp (0.6 Honduras - 58 Mexico). The mean number of nephrologists is 16 pmp 
(2 Colombia - 53 Uruguay). Non-communicable diseases are the main cause of CKD in Latin 
America, with 36% of KRT patients developing CKD due to diabetes (~70% in Mexico and Puerto 
Rico). Besides the traditional causes of CKD, Mesoamerican Nephropathy is an incompletely known 
form of CKD, affecting men working under disadvantaged conditions in agricultural areas of Central 
America. Although advances have been made, there is a need to support local and regional research 
on this topic to further understand how to prevent and treat this and other forms of the disease. 
The South African Renal Registry (SARR) is, thus far, the only regularly published and updated 
report of KRT in sub-Saharan Africa. The SARR was first published in 2014 (based on 2012 data) 
with the data demonstrating a significant inequality in the distribution of KRT across provinces and 
between the public and private health sectors in South Africa. A more recent SARR report (based on 
2015 data) showed an ESKD treatment rate of 71.9 pmp in the public sector (representing a 
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population of 46.2 million) versus 799.3 pmp in the private sector (representing a population of 8.8 
million). It is hoped that these reports will influence government to respond with measures to improve 
the care of patients with kidney diseases. The SARR reports have influenced the African Association 
of Nephrology (AFRAN) to adapt its methods and use the same platform to develop an African Renal 
Registry. However, only four countries (Ghana, Burundi, Zambia, and South Africa) are currently 
participating in data collection (personal communication with Prof. Razeen Davids). Low 
participation in the African Renal Registry could limit the usefulness of reported data. 
Initiatives to support the implementation of KRT registries in LMIC 
Consideration could also be given to incorporating resource-limited countries into existing registries, 
as has happened on occasion with North African countries contributing to the European Renal 
Association – European Dialysis and Transplant Association (ERA-EDTA) Registry48,52 and the 
United States Renal Data System (USRDS) registry.9 Pacific Island countries, such as Fiji, could 
leverage the infrastructure and collaborative expertise of the Australian and New Zealand Dialysis and 
Transplant (ANZDATA) Registry. Recently, agreement was reached between AFRAN and the 
African Paediatric Nephrology Association (AFPNA) to establish the African Renal Registry, which 
will use the shared web-based technology platform and common data dictionary of the South African 
Renal Registry.48 
Moreover, the Latin American Society of Nephrology and Hypertension (SLANH), which coordinates 
the LADRTR, is promoting action in the area of training and capacity building, namely courses and 
training opportunities for national registries (Cueto-Manzano, personal communication). The aim is to 
create more national ESKD registries (to have one in every country of the region) and increase their 
quality as a key step in determining the true burden of kidney disease and outcomes for patients. 
SLANH has established an active training program in conjunction with Pan American Health 
Organization (PAHO), the national societies of Nephrology and the Ministry of Health of every 
country, to develop regional and national registries. An important challenge is the lack of a normative 
policy frame for the registry functioning. In most countries, the registry is voluntary and only 
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administered by its national society of nephrology (no participation of the Ministry of Health), 
without human or economic resources. Countries with more developed registries have 
institutionalized their functioning: they have a committee with all the relevant stakeholders, have a 
normative frame, reporting is mandatory, and health authorities are actively involved in providing 
technology infrastructure, as well as economic guarantees and human resources.  
The ISN is supporting these efforts through the Sharing Expertise to support the set-up of Renal 
Registries (SharE-RR) project (https://www.theisn.org/advocacy/share-rr), which is developing a 
resource available to kidney health advocates in countries wishing to establish or develop a renal 
registry to support advocacy, quality assurance, and research. This project will facilitate sharing of 
registry policies, procedures, governance structures, databases, datasets, technology platforms, files, 
and consent processes. Surveys of existing registries will be conducted to help inform the 
establishment of a minimum dataset to be collected by all renal registries to permit benchmarking 
between registries and to monitor the quality of care and outcomes. A minimum dataset will help 
healthcare professionals and people with ESKD make better informed treatment decisions and capture 
serious health-related suffering in people with ESKD for inclusion in global health reports. 
Additional strategies to optimize the information capture from health information systems 
Registry data linked with geographic information systems can monitor variations in ESKD prevalence 
and identify “hot spots” and areas where there are major mismatches between KRT supply and 
demand.53 Registry output and reports should be freely accessible online to maximize reach, 
transparency, and impact.48 A systematic review of renal registries reported that “public accessibility 
to annual reports, publications, or basic data was good for 17 (35%) registries.”54 
Benchmarking will be facilitated by developing standardized definitions and terminology (data 
dictionary) for registries. For example, ESKD is variously defined around the world, ranging from 
requirement for KRT to estimated glomerular filtration rate <15mL/min/1.73 m2. This definition and 
other important variables collected in registries need to be revised and harmonized. Defining 
conservative care for capture by registries has proven challenging, with very limited data available on 
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numbers treated conservatively and the components and quality of that care. It is necessary to define 
the initiation of conservative care if registries are to measure it and report on quality of care. For 
similar reasons, it is also necessary to agree on a definition for discontinuation of dialysis. 
Data captured in ESKD Registries could be supplemented with data from observational studies. The 
implementation of representative cohort studies in LMIC, such as Peritoneal Dialysis Outcomes and 
Practice Patterns Study (PDOPPS) in Thailand and Colombia, CKDOPPS in Brazil, and DOPPS in 
China are examples of how observational studies can be useful in generating information related to 
the kidney care in LMIC where registries are not available. In Brazil, the implementation of a local 
and nationally representative observational study (BRAZPD) provided information about the reality 
of PD treatment in a country where a PD registry was not available.55 Granular information on patient 
characteristics, local practice, and factors associated with clinical outcomes, usually not captured in 
registries, can be a valuable (and complementary) addition to the information from registries.  
Finally, innovative information technologies could improve the capturing of data through automated 
extraction from electronic health records, data linkage from multiple sources, and simplified 
collection of patient level data using mobile phones or personal computers and web-based platforms.  
Final considerations 
To capture, monitor, and map the journeys of patients’ kidney disease, ESKD registries should be 
linked to primary and secondary care to map patient flow, the impact of improved CKD care, and 
outcomes of interventions. Key patient-centered performance indicators and outcome measures in 
KRT modalities (including conservative care) should be captured to measure quality of care and 
patients’ preferences. In addition, registries should be integrated within countries and regions, such 
that pediatric and adult registries are combined and all forms of ESKD care (including dialysis, 
transplantation, comprehensive conservative care, and choice-restricted conservative care) are 
captured and supplemented with observational studies. Ideally, the focus of renal registries should 
shift from modality-centered to person-centered. Finally, registries should be utilized to help design 
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and implement clinical trials. Initiatives to provide support for registry implementation and training 
and sharing experiences could help in the development and implementation of local registries.  
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Figure 1: Availability of renal (dialysis and transplantation) registries across the globe.  
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